ALX Oncology Statistics
Share Statistics
ALX Oncology has 52.74M shares outstanding. The number of shares has increased by 5.73% in one year.
| Shares Outstanding | 52.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.1% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 34.30M |
| Failed to Deliver (FTD) Shares | 57.63K |
| FTD / Avg. Volume | 7.21% |
Short Selling Information
The latest short interest is 7.84M, so 14.87% of the outstanding shares have been sold short.
| Short Interest | 7.84M |
| Short % of Shares Out | 14.87% |
| Short % of Float | 22.84% |
| Short Ratio (days to cover) | 11.81 |
Valuation Ratios
The PE ratio is -3.98 and the forward PE ratio is -0.49.
| PE Ratio | -3.98 |
| Forward PE | -0.49 |
| PS Ratio | 0 |
| Forward PS | 122.4 |
| PB Ratio | 3.37 |
| P/FCF Ratio | -4.86 |
| PEG Ratio | n/a |
Enterprise Valuation
ALX Oncology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.24, with a Debt / Equity ratio of 0.05.
| Current Ratio | 5.24 |
| Quick Ratio | 5.24 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.84 |
| Cash Flow / Debt | -13.52 |
| Interest Coverage | -108.8 |
Financial Efficiency
Return on equity (ROE) is -0.85% and return on capital (ROIC) is -82.3%.
| Return on Equity (ROE) | -0.85% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | -82.3% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.81M |
| Employee Count | 89 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -89.3% in the last 52 weeks. The beta is 1.04, so ALX Oncology 's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | -89.3% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 6.8 |
| Relative Strength Index (RSI) | 45.29 |
| Average Volume (20 Days) | 799.58K |
Income Statement
In the last 12 months, ALX Oncology had revenue of $0 and earned -$160.81M in profits. Earnings per share was $-3.74.
| Revenue | 0 |
| Gross Profit | -836.00K |
| Operating Income | -170.28M |
| Net Income | -160.81M |
| EBITDA | -158.40M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.74 |
Balance Sheet
The company has $22.41M in cash and $17.20M in debt, giving a net cash position of $5.21M.
| Cash & Cash Equivalents | 22.41M |
| Total Debt | 17.20M |
| Net Cash | 5.21M |
| Retained Earnings | -486.27M |
| Total Assets | 185.72M |
| Working Capital | 123.56M |
Cash Flow
In the last 12 months, operating cash flow was -$130.36M and capital expenditures -$1.27M, giving a free cash flow of -$131.64M.
| Operating Cash Flow | -130.36M |
| Capital Expenditures | -1.27M |
| Free Cash Flow | -131.64M |
| FCF Per Share | -3.06 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ALXO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -257.93% |
| FCF Yield | -172.13% |
Analyst Forecast
The average price target for ALXO is $12.5, which is 762.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.5 |
| Price Target Difference | 762.1% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -5.37 |
| Piotroski F-Score | 2 |